AMSBIO has introduced a cutting-edge range of genetically engineered Induced Pluripotent Stem Cells (iPSCs) designed to enhance model fidelity in drug discovery and cell therapy research. These iPSCs outperform traditional cell lines and biochemical assays, offering significant improvements in efficiency and cost-effectiveness over animal models. The new collection includes iPSCs engineered to express Cas9 either constitutively or via doxycycline induction (tet-on), facilitating targeted gene manipulation for generating knockout, mutated, or knock-in cells.
The use of CRISPR/Cas9 technology in these iPSCs allows researchers to selectively knockout target proteins, providing valuable insights into cellular behavior. AMSBIO’s B2M Knockout iPS cell line, with its low immunogenicity, presents a powerful tool for allogeneic cell therapy research. Additionally, the new StemBright™ Reporter iPSCs are engineered to express a conditional reporter gene, enabling responsive tracking and analysis of cell signaling pathways.
AMSBIO also offers custom iPSC services to accelerate research, including the design of tailored iPSCs, large-scale cell differentiation, and compound screening on iPSC-derived cells, providing researchers with versatile tools to advance their studies.
This article is a summary of a published press release
